CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 9 enrolled
Drug / intervention
Hyperpolarized Carbon C 13 Pyruvate +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03565367
NCT03565367Phase 1Completed

A Pilot Study to Assess Lactate and Bicarbonate Detection Within Malignant Brain Tumors Using [1-13C]-Pyruvate DNP Magnetic Resonance Spectroscopy (MRS)

Daniel M. Spielman·interventional·Posted Jun 21, 2018·Updated Dec 21, 2023

In Brief

A Phase 1 clinical trial evaluating Gadolinium, Hyperpolarized Carbon C 13 Pyruvate, and 2 other interventions for Malignant Central Nervous System Neoplasm and Metastatic Malignant Neoplasm in the Central Nervous System. Completed, enrolled 9 participants across 1 site.

Detailed Summary

This early phase I trial studies how well hyperpolarized carbon C 13 pyruvate magnetic resonance imaging works in detecting lactate and bicarbonate in participants with central nervous system tumors. Hyperpolarized carbon C 13 pyruvate magnetic resonance imaging may be used to measure the metabolic state of malignant brain tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJun 21, 2018
Enrollment StartNov 6, 2018
Primary CompletionJun 20, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.0 years ago

Interventions

Gadoliniumother

gadolinium enhanced MRI

Hyperpolarized Carbon C 13 Pyruvatedrug

Given IV

Magnetic Resonance Imagingprocedure

Undergo MRI

Magnetic Resonance Spectroscopic Imagingprocedure

Undergo MRSI